ValueinValuein

ACRVAcrivon Therapeutics, Inc.

Health Care

Lease, Cost revised down 4.1% for Q1 2025

This is the 2nd largest revision in ACRV's history.

Lease, Cost

Q1 2025

Notable restatement

As reported

$417K

Restated

$400K
-4.1%
Verify against SEC filingsShow
As reported$417K
Accepted 2025-05-140000950170-25-071427
Restated$400K
Accepted 2026-05-130001193125-26-221634

RentAndOccupancy · reported 4 times · point-in-time, survivorship-free. Every figure traces to its filing above.

Track this the moment it happens

Get an alert the next time ACRV — or any company on your watchlist — restates a number. Every alert lands with the diff and its source filing.